Lunai Bioworks (LNAI)
Biomedical-AI analytics and zebrafish screening for preclinical discovery.
Something off on this page? Send us feedback.
Provides biomedical-AI analytics and zebrafish phenotypic screening through BioSymetrics, earning service revenue from research engagements while RENB advances preclinical oncology and neurology programs. The company has no regulatory-approved products.
Combines BioSymetrics' multimodal data analytics with zebrafish phenotypic screening to support biomarker discovery, therapeutic development, and precision medicine. Its Augusta, Phenograph, and in-vivo modeling components link genomic, proteomic, and phenotypic data to experimental validation.
Operates from Sacramento in a distributed-first model, with work spanning the United States and Canada. BioSymetrics provides the only recognized service revenue, while RENB advances preclinical oncology and neurology programs and the company has added CNS-delivery patent rights.
Has no regulatory-approved products; therapeutic programs require further preclinical and clinical evidence and regulatory authorization. Operations depend on additional financing following losses and February furloughs, and Nasdaq has placed it under a mandatory panel monitor with reduced cure flexibility following its bid-price compliance.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $3.2M · Total debt $1.4M · Total assets $9.9M · Shareholders' equity −$9.6M
- Revenue
- $20.9K
- Operating income
- −$1.4M
- Net income
- −$2.6M
No dividends on record.
No ownership filings on record for this listing.
- Recursion Pharmaceuticals
AI-native discovery platform contests biopharma R&D workflows.
- Tempus AI
Multimodal data and AI contest precision-medicine research work.
- Schrödinger
Physics-plus-AI molecular discovery overlaps preclinical R&D.
- GRAIL
Multi-cancer blood testing contests oncology biomarker discovery.
- Freenome
AI and multiomic blood testing overlap cancer biomarker work.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lunai Bioworks | $2.33 | −4.12% | $10.9M | — | — | 519.6 | — |
| Recursion Pharmaceuticals | $3.38 | +0.15% | $1.77B | — | — | 32.3 | −61.8% |
| Tempus AI | $61.78 | −0.21% | $10.85B | — | — | 7.6 | +21.6% |
| Schrödinger | $20.76 | −0.57% | $1.56B | — | — | 6.0 | +7.5% |
| GRAIL | $80.56 | +0.11% | $3.46B | — | — | 20.9 | +25.7% |
| Freenome | $15.79 | −1.00% | $130.1M | — | — | — | — |
| Median | — | — | 14.2 | +14.5% |